Investigating the NKG2A pathway to treat hair loss in alopecia areata
Official title: Targeting the NKG2A Pathway in Alopecia Areata
Funded at Columbia University Health Sciences · NIH-11051236 · Data updated 2026-11-12
This study is looking at alopecia areata, a condition that causes hair loss, and is exploring new ways to help by targeting certain immune cells; if you're dealing with this condition, you might have a chance to join trials testing these exciting new treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 6, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $548,035 |
| NIH project number | 5R01AR084005-02 |
| Project ID | NIH-11051236 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with alopecia areata who are experiencing hair loss.
✕Less likely to help
Patients with other forms of hair loss not related to autoimmune conditions may not benefit from this research.
What this research studies
This research focuses on alopecia areata, a chronic autoimmune condition that leads to hair loss. The team has identified specific immune cells that contribute to the disease and is exploring how targeting the NKG2A pathway can help regulate these cells. By using advanced techniques like single-cell RNA sequencing, they aim to understand the immune response better and develop new treatment strategies. Patients may have the opportunity to participate in trials that test these innovative therapies.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for patients suffering from alopecia areata.
How similar studies have gone: Previous research has shown promise in targeting immune pathways for autoimmune conditions, suggesting potential success for this approach.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Christiano, Angela M — Columbia University Health Sciences
- Study coordinator: Christiano, Angela M
Related research
Other NIH-funded projects on the same topics.
-
Dupilumab for hair regrowth in children with alopecia areata
This project gives dupilumab to children and teens with widespread alopecia areata, especially those with allergies or high IgE, to help their hair grow back.
-
Targeting the NKG2A immune pathway to treat alopecia areata
This project will try blocking the NKG2A immune signal to reduce the immune attack on hair follicles and help people with alopecia areata regrow hair.
-
How IL-27 affects hair loss in alopecia areata
Researchers are exploring whether the immune molecule IL-27 helps stop the immune attack that causes hair loss in people with alopecia areata.
-
Using hydrogels to treat hair loss in alopecia areata
This study is exploring a new gel treatment for people with alopecia areata, a condition that causes hair loss, to see if it can help stimulate hair regrowth in a safe and effective way.
-
Using dupilumab to treat hair loss in children with alopecia areata
This study is looking at how a medication called dupilumab can help kids with alopecia areata, a condition that causes hair loss, by encouraging hair regrowth and making sure the treatment is safe and effective for them.
-
Investigating the role of IL-27 in hair loss caused by autoimmune disease
This study is looking at how a substance called IL-27 affects the immune system in people with alopecia areata, a condition that causes hair loss, to find new ways to help treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.